Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -154.99% | 36.35% | 72.88% | 69.86% |
| Total Depreciation and Amortization | -- | -30.59% | -2.82% | 72.30% | 34.89% |
| Total Amortization of Deferred Charges | -- | -- | 72.79% | -- | -- |
| Total Other Non-Cash Items | -- | 113.48% | -65.59% | -27.74% | -130.05% |
| Change in Net Operating Assets | -- | 195.44% | 756.30% | -122.77% | 1,292.23% |
| Cash from Operations | -- | 44.78% | 321.13% | -14.21% | 253.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -108.62% | -101.54% | -98.98% | -33.14% |
| Cash from Investing | -- | -108.62% | -101.54% | -99.12% | -33.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -72.95% | -100.00% | -98.85% |
| Repurchase of Common Stock | -- | 64.56% | 96.93% | 94.29% | -460.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 92.38% | 13,489.71% |
| Cash from Financing | -- | -129.76% | -36.89% | -101.50% | -445.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -127.78% | 25.03% | -939.87% | -277.08% |